Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...
Samsung Biologics reports third quarter 2025 financial results
Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion Recorded Q3'25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea,...
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of...